If you are not happy with the results below please do another search
Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels. Details of the assesment see here
Dualsystems Biotech AG Press Release Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to…
